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Abstract 
Hedgehog (Hh) signaling promotes tumorigenesis. The accumulation of a membrane 
protein Smoothened (Smo) within the primary cilium (PC) is a key event in Hh signal 
transduction and many pharmacological inhibitors identified to date target Smo’s actions.  
Smo ciliary translocation is inhibited by some pathway antagonists while others promote 
ciliary accumulation; an outcome that can lead to a hypersensitive state on renewal of Hh 
signaling.. To identify novel inhibitory compounds acting on the critical mechanistic 
transition of Smo accumulation, we established a high content screen to directly analyze 
Smo ciliary translocation. Screening thousands of compounds from annotated libraries of 
approved drugs and other agents, we identified several new classes of compounds that 
block Sonic hedgehog-driven Smo localization within the PC. Selective analysis was 
conducted on two classes of Smo antagonists. One of these, DY131, appears to inhibit 
Smo signaling through a common binding site shared by previously reported Smo 
agonists and antagonists. Antagonism by this class of compound is competed by high 
doses of Smo-binding agonists such as SAG, and impaired by a mutation that generates a 
ligand independent, oncogenic form of Smo (SmoM2). In contrast, a second antagonist of 
Smo accumulation within the PC, SMANT, was less sensitive to SAG-mediated 
competition, and inhibited SmoM2 at similar concentrations to those that inhibit wild-
type Smo. Our observations identify important differences among Hh antagonists and the 
potential for development of novel therapeutic approaches against mutant forms of Smo 
that are resistant to current therapeutic strategies. 
 3 
 
Introduction 
    Hedgehog (Hh) signaling plays an essential role in developmental processes and adult 
tissue homeostasis(1). An increasing body of evidence identifies the Hh pathway as a 
contributing factor in the growth of a variety of human cancers. The loss of normal 
regulatory control of the Hh pathway within a subset of Hh responsive cells leads directly 
to the initiation of particular solid tumors, notably basal cell carcinoma (BCC), the most 
prevalent cancer in the Caucasian population(2), and medulloblastoma (MB), the most 
common childhood brain cancer(3).   In other cancers, Hh signals from tumor cells 
appear to condition the local environment to favor tumor growth. This category includes 
a broad spectrum of high incidence cancers, particularlythose in breast, lung, liver, 
stomach, pancreas, prostate, and gastro-intestinal tract (4-5). The potential of Hh targeted 
cancer therapy has stimulated an extensive search for Hh pathway antagonists. Typically, 
drug discovery screens have broadly sampled the Hh pathway looking for agents capable 
of silencing a Hh signal-dependent transcriptional response.  Although small-molecule 
“hits” may occur at any point in the pathway that can ultimately translate into an altered 
transcriptional response, Smoothened (Smo), has emerged as the prevalent target. (6-
7)Smo is essential for all pathway activity, and activating mutations in Smo have been 
observed in both human BCC and MB. Smo antagonists have entered clinical trials(8), 
andsuccessful repression of tumorigenesis in patients with invasive or metastatic forms of 
BCC has validated the concept of Hh targeted cancer therapy(9). The leading drug, 
GDC0449 (now marketed as Erivedge), was recently approved by the US Food and Drug 
Administration(FDA) for treatment of advanced BCC(10)(10)(10). 4 
 
An obligatory step in the activation of Hh signaling is the accumulation of Smo in the 
primary cilium (PC), a tubulin-scaffolded membrane extension templated by the centriole 
(Supplementary Fig. 1). While all small molecule Smo agonists examined so far induce 
Smo accumulation in the PC, various Smo antagonists affect Smo localization in distinct 
ways (Supplementary Fig. 1) (11-13). SANT-1, SANT-2, and GDC0449 inhibit both Hh 
pathway activation and Sonic hedgehog (Shh) induced Smo accumulation within the 
PC(11-13).In contrast, Cyclopamine (cyc), a natural product from the plant Veratrum 
californicum, and its potent derivative KAAD-cyc, bind Smo and inhibit pathway 
activation, but behave as  pseudo-agonists promoting Smo accumulation within the 
PC(11-14). Further, forskolin (FKL), a putative protein kinase A (PKA) activator, 
inhibits Hh pathway activity and indirectly promotes Smo ciliary accumulation through 
PKA stimulation(11). Thus, there are distinct actions and outcomes associated with 
different inhibitory factors grouped around Smo action (Supplementary Fig. 1). 
To explore regulatory activity at this critical level of pathway action, we performed a 
direct screen for inhibitors of Smo translocation to the PC and identified 20 classes of 
inhibitory compounds. We identified some novel compounds that may act on Smo in a 
similar manner to previously identified antagonists and agonists, underscoring the 
chemical diversity of compound interactions at what is possibly a common site. However, 
we also identified a new compound, SMANT, which inhibits an oncogenic form of Smo 
refractory to inhibition by currently available Smo antagonists.  
 
Results 
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Screening for antagonists of Smo translocation to the primary cilium 
In work to be published elsewhere, we have established a high content screen for 
modulators of Smo translocation focusing on small molecules stimulating Smo 
translocation to the PC (Wang Y. et al., under revision). We then modified the system to 
identify inhibitors of Smo ciliary translocation. In brief,we developed a cell line 
producing human Smo::EGFP and Ivs::tagRFPT fusion proteins. Ivs::tagRFPT highlights 
the PC, and GFP enables the cellular trafficking of Smo to be visualized. Test compounds 
were added in low serum medium for 18-24 hours in the presence of Shh, cells were then 
fixed and stained with Hoechst(Supplementary Fig.2). Quantitative multi-parametric 
image analyses were performed with custom algorithms (For details, please refer to 
Materials and Methods). The most critical parameters measured are indicated in Fig. 1a: 
Cell number was measured by counting Hoechst-labeled nuclei whereas the PC was 
precisely segmented as an Ivs::tagRFPT positive structure; the specific PC localization of 
Smo::EGFP was discerned by applying a defined threshold for the length-width ratio of 
Ivs::tagRFPT positive structures (inset in Ivs::tagRFPT images) and then quantifying 
hSmo::EGFP intensity within the Ivs::tagRFPT positive PC. Key measurements from 
these analyses are shown for GDC0449 (Fig.1b and c) and SANT-1 (Supplementary Fig. 
3). As expected, each specifically inhibited Smo::EGFP accumulation in the PC without 
causing significant structural changes to the PC itself or measurable cytotoxicity(15-16).  
 
   We used this high content assay to screen a collection of approximately 5,600 small 
molecules for compounds that block Smo accumulation in the presence of Shh. The small 6 
 
molecule library includes FDA approved drugs, drug candidatesin preclinical or clinical 
development and a group of compounds with annotated biological activity.Representative 
examples of assay plates are shown (Supplementary Fig. 4). Z-prime scores(17)were 
consistently >0.6, confirming the robustnessof the screen.   
    We first eliminated small molecules with “off-target” effects, e.g. inhibitory effects on 
ciliary assembly/trafficking or general cytotoxicity.  For example, HPI-4, a molecule that 
leads to truncation or loss of the PC (18), and vinblastine, a drug known to disrupt the 
assembly of microtubules (19), both appear as Hh pathway antagonists in a Gli-luciferase 
reporter assay (Fig.2 a and c). However, the decrease in the Ivs::tagRFPT ciliary signal in 
the Smo high-content assay indicates a non-specific mechanism that alters PC structure 
(Fig. 2).  
We identified 26 validated hits that could be divided into 20 classes. These hits include 
known Hh pathway inhibitors such as AntagVIII, a potent phenyl quinazolinone urea 
derivative (Supplementary Fig. 5)(20). Moreover, identification of AY9944, an inhibitor 
of cholesterol biosynthesis and esterification(21),adds additional support to the proposed 
intersection between cholesterol metabolism and the Hh pathway
26. Hh ligands are 
covalently modified by cholesterol
27 and Hh trafficking has been linked to cholesterol 
transport processes (22-23)
,29but in vitro studies suggest the response of the target cell is 
actually suppressed when cholesterol biosynthesis is blocked(24).Our data suggest a 
potential link with Smo accumulation within the PC (Supplementary Fig. 6). Further, in 
line with a recent report (25), our screen identified itraconazole and ketoconazole, two 
anti-fungal drugs in current clinical use, as Smo inhibitors in the ciliary-based assay 7 
 
(Supplementary Fig. 7).  In all cases examined, compounds that blocked Smo 
translocation to the PC inhibited Gli transcription activity (Supplementary Figs 5-7).  
 
DY131 inhibits Smo signaling through a conventional mechanism. 
Of the novel compounds, we first selected DY131, a potent hit, for subsequent analysis. 
DY131, and its analog GSK4716, inhibited Shh induced accumulation of Smo::EGFP 
with IC50’s of 0.8 µM and 2µM respectively (Fig. 3a-c, Supplementary Fig. 8, Table 1). 
Both DY131 and GSK4716 inhibit Shh induced activation of a Gli-reporter with 
somewhat higher IC50’s (2µM and 10µM respectively) (Fig. 3d). The absence of an 
inhibitory activity in a Wnt pathway reporter assay argues for a specific action of DY131 
in suppressing Shh action (Supplementary Fig. 9).  
    DY131 and GSK4716 were previously identified as agonists of the estrogen related 
receptors (ERR) (26-27). However, other ERR/ER ligands, including tamoxifen citrate, 
4-hydroxytamoxifen (4-OHT), diethylstilbestrol, and hexestrol, did not alter the 
accumulation of Smo on the PC in either the presence or absence of Shh(Supplementary 
Fig. 10), arguing against an ERR-based mode of action for DY131 and GSK4716. 
  To investigate at what level DY131 functions in the Hh pathway, we compared the 
drug’s dose-dependent performance in inhibiting the activities of wild-type Smo and 
SmoM2 (also named SMOA1), a constitutively active form of Smo with a tryptophan to 
leucine mutation in the 7
th transmembrane domain(2).  This mutation renders Smo 
markedly less sensitive (IC50’s for SmoM2 are more than an order of magnitude higher 
than IC50’s for wildtype Smo) to Cyc, SANT-1 and GDC0449-mediated inhibition (15-
16, 28) (Supplementary Figs 11-12). When over-expressed, both wild-type Smo and 8 
 
SmoM2 constitutively localize to the primary cilium (6, 29). In contrast to its potent 
inhibition ofthe ciliary accumulation of wild-type Smo following exposure to Hh 
ligand(Fig.3c), or over-expression of wild-type Smo(Fig. 3 e and f), DY131 failed to 
inhibit ciliary localization of SmoM2, or SmoM2 driven activation of transcriptional 
reporters of pathway activity, at doses up to 30µM (Fig.3 e-g). However, DY131 
suppressed SAG (100nM) induced accumulation of Smo::EGFP in the primary cilium 
and Gli transcription activity with an IC50 of approximately 2µM (Supplementary Fig. 
13). 
 Interestingly, SANT-1 and GDC0449, at a dose high enough to block SmoM2 activity, 
did not alter SmoM2 ciliary accumulation, suggesting that, as with wild-type Smo, 
activity of this mutant can be abolished without blocking its localization to the PC 
(Supplementary Figs 11).   
   To determine if DY131 binds directly to Smo, we used a competition assay with 
bodipy-Cyc, a fluorescent analog of Cyc(30). Bodipy-Cyc specifically labels cells over-
expressing Smo, co-expressing a red, nuclear fluorescent protein (Nuc-tagRFPT) marker, 
whereas SmoM2-expressing cells do not bind bodipy-Cyc, confirming the specificity of 
this assay (Fig. 3 h and i). DY131, like Cyc and SANT-1, acts as an effective competitor 
of bodipy-Cyc labeling of cells overexpressing Smo, consistent with either direct binding 
to Smo at the same site as bodipy-Cyc, or at another site on Smo resulting in allosteric 
modification and loss of bodipy-Cyc binding(Fig. 3 h and i).  
 
SMANT inhibits Smo signaling with anovel mechanism. 9 
 
Our data suggest that DY131 and its analogs inhibit Hh signaling through a similar 
mechanism to inhibitors such as Cyc, SANT-1, and GDC0449. However, our focused 
effort in characterizing most potent hits from the screen also identified small molecules 
displaying novel behaviors.  We named one compound, Smo Mutant ANTagonist 
(SMANT) as it exhibited an equivalent activity in inhibiting SmoM2 and wild-type Smo 
(Fig. 4a and h). SMANT and its analog SMANT-2 inhibited Shh induced ciliary 
accumulation of Smo::EGFP with IC50’s of 1.1µM and 1.6µM, respectively (Fig.4b and 
c; Table 1). Neither resulted in altered Ivs::tagRFPT localization at the PC or profound 
modulation of Wnt pathway activity consistent with a Hh pathway specific mode of 
action (Fig. 4b; Supplementary Fig. 14 and 15).  
As with DY131, SANT-1, and GDC0449 (Fig. 3e and f, Supplementary Fig. 11), 
SMANT failed to block SmoM2::EGFP localization to the PC while potently inhibiting 
wild-type Smo accumulation (Fig. 4d and e). In contrast to some of the other Smo 
antagonists, SMANT failed to block Smo ciliary localization induced by SAG or Cyc 
(Fig. 4f and g; Supplementary Fig. 16; Supplementary Fig. 13a and b). However, in 
contrast to other pathway inhibitors, SMANT was similarly effective at inhibiting Smo 
and SmoM2 activity, and blocked the stimulatory action of SAG at different 
concentrations in the Gli-luciferase assay (Fig. 3d, 3g and 4h; Supplementary Fig. 12 and 
13c). SMANT, like DY131 and GDC0449, and distinct from GANT61(31), a known Gli 
inhibitor, does not alter Hh pathway activation induced by loss of suFU, a Gli regulatory 
factor (Fig. 4i), suggesting that SMANT functions at the Smo level. However, in contrast 
with strong competition between DY131 and Cyc for binding Smo (Fig.3h and i), 10 
 
SMANT was a poor competitor (Fig. 4j and k), consistent with a unique inhibitory action 
on Smo activity.  
 
DY131 and SMANT effectively inhibit Hh signaling without the risk of rebound 
hyperactivity. 
To further explore the potential utility of compounds found in our assay for developing 
anti-cancer agents for Hh pathway targeted therapies, we tested DY131 and SMANT on 
cultured cerebellar granule neuron precursors (CGNPs) isolated from Ptch1+/- neonates. 
Constitutive activation of Hh signaling in these cells is associated with medulloblastoma 
(32). Consistent with their potency in inhibiting Hh activity in NIH/3T3 cells, DY131 and 
SMANT dramatically decreased phosphorylated histone H3 (pH3) marked proliferation 
of CGNPs induced by Shh(Fig. 5 a-b).  
Finally, we primed cells with GDC0449, Cyc, FKL or SANT-1 at doses sufficient to 
decrease both Smo ciliary localization and Gli mediated transcription activity for 24 
hours (Supplementary Fig. 1). Following the removal of drug containing medium, and 
extensive washing, cells were stimulated with either Hh ligand, or the direct-binding Smo 
agonist SAG (16, 33). As predicted, we observed an elevated signaling response 
specifically in Cyc and FKL treated cells (Supplementary Fig. 17a, Supplementary Fig. 
18). The hypersensitivity to Hh pathway activation correlated with high levels of Smo 
that remained within the PC following removal of the antagonizing compound 
(Supplementary Fig. 17b-e). Next we tested the consequences of this effect for newly 
identified DY131 and SMANT using NIH3T3 cells (Fig. 5c) and CGNPs (Fig. 5 d-e).  In 
contrast to Cyc, we observed no Shh driven hyperactivation of Hh pathway activity on 11 
 
removal of DY131 or SMANT in either the NIH3T3 Gli-luciferase assay or the CGNP 
proliferation assay. 
 
Discussion 
Based on evidence presented here, compounds that inhibit both pathway activity and 
Smo accumulation in the primary cilium have characteristics that may make them 
reasonably preferred to antagonists that themselves promote ciliary accumulation of Smo. 
Therefore, the type of high content screen that we have established, which directly 
quantifies the Smo-PC interactions required for Hh pathway activity, is useful both for 
discovering new classes of antagonists, as well as for studying existing ones.The current 
screen, of over 5,000 compounds, selectively identified a substantial number of small 
molecules with efficacy in this assay, and more conventional Hh pathway assays. While 
careful analysis of DY131 suggests a direct interaction with Smo, SMANT shows a 
unique profile inhibiting an oncogenic form of Smo carrying the M2 mutation with 
similar efficacy to its wild-type counterpart. The differing properties of SMANT when 
compared with a variety of other Smo modulators (SAG, Cyc, GDC0449, and SANT-1) 
are consistent with a SMANT inhibitory action at a different site on Smo to that bound by 
these other compounds, or an indirect modulation of Smo activity. Smo can be 
inactivated in the PC by SMANT when harboring the M2 mutation, or after SAG driven 
translocation to the PC, suggesting that SMANT may inactivate both the oncogenic form 
and an SAG-bound form of Smo, and more importantly, the ciliary localization of Smo 
and its activation may be mechanistically divergent. It is possible that post-translational 
modifications, conformation changes, or interacting partners that regulate ciliary entry or 12 
 
accumulation of Smo differ from those governing activity in the primary cilium.(34-35) 
Frequently, compounds show a higher potency in the inhibition of Smo localization to the 
primary cilium than that in Gli-luciferase assays (Fig.3c and d, Fig.4 c and h, 
Supplementary Fig. 5-7). This could reflect pathway activity while Smo is out of the PC, 
or the different time frames involved in the two assay systems.  
 
Our studies highlight new opportunities for therapeutic development that may 
potentiate existing approaches and over new strategies towards treatment of resistant 
forms of Smo emerging from somatic mutation. The screening platform provides a robust 
assay system. The Smo ciliary screen broadly interrogates a key aspect of HH pathway 
regulation and biology, and potentially identifies small molecule regulators that may not 
score in a conventional transcriptional end-point assay. These compounds may 
nevertheless provide a reasonable grounding for subsequent drug development. Further, 
the screen enables a stratification of small molecule function in the HH pathway and a 
platform that can be extended to potentially explore ciliopathies, an increasingly 
important area of medical significance (36).  
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Materials and Methods 
Cell Culture 
NIH/3T3 cells were maintained in DMEM containing 10%(v/v) calf serum, penicillin, 
streptomycin, and L-glutamine. HEK293, L,cos7, and suFU-/- mouse embryonic 
fibroblast cells were maintained in DMEM containing 10%(v/v) fetal bovine serum, 
penicillin, streptomycin, and L-glutamine. Smo::EGFP, SmoM2::GFP, and Ivs::tagRFPT 
were cloned into pBabe to generate retroviral particles for infection. 
Smo::EGFP/Ivs::tagRFPT and SmoM2::GFP/Ivs::tagRFPT stable cell lines were 
generated through viral infection of NIH/3T3 (13). A ShhLightII Gli reporter cell line 
was obtained from the American Type Culture Collection (ATCC) and used in luciferase 
reporter assays to measure Hh pathway activity. The cell line contains a stably integrated 
Gli-responsive Firefly luciferase reporter and a constitutive Renilla luciferase expression 14 
 
construct (28). Subclones expressing Smo or SmoM2 in ShhLightII cells were used for 
chemical epistasis analyses.  
Shh conditioned medium, which is collected from cos7 cells transfected with an 
expression construct encoding the amino terminal 19kDa signaling peptide of Shh, was 
used at 13.7(±3.0)nM. Wnt3a conditioned medium was collected from an L-cell line 
producingWnt3a ligand(37). Controls utilized supernatants from cells cos7 cells 
transfected with empty vector or a wild-type L-cell line.  
Reagents 
Cyclopamine and forskolin were purchased from Sigma. SAG, SANT-1, GDC0449, and 
BODIPY-cyclopamine were purchased from Axxora Platform, Tocris Biosciences, 
Selleck Chemicals, and Toronto Research Chemicals, respectively. All small molecule 
stock solutions were prepared by dissolving in DMSO at 10 mM and stored at -20
￿C. 
Mouse recombinant ShhN purified protein (IIShhN) was purchased from R&D Systems.  
Transfection was performed using Fugene6 or Fugene HD from Roche. 
Imaging Assays 
Cells were cultured and treated in 384-well imaging plate precoated with poly-D-Lysine 
(Greiner Bio-one), fixed with 4%(w/v) paraformaldehyde (Electron Microscopy 
Sciences), and stained with Hoechst(Invitrogen). Images were collected using Opera 
High Content Screening System (Perkin Elmer).ActivityBase (IDBS Inc,) and Pipeline 
Pilot (Accelrys, Inc.) were used for high content screening data management and 
analysis.  
Image Analysis of Smo Ciliary Localization 15 
 
Acapella 2.0 software (Evotec Technologies/PerkinElmer) was used to perform multi-
parametric high content image quantification. Our image analysis script used 
Ivs::tagRFPT to first determine the location of the PC and then Smo::EGFP to quantify 
the level of Smo present in the cilium. 
First, we used the spot-finding algorithm in the RFP channel to find Ivs-rich 
spots.  Each non-overlapping spot was based on a maximum 8 pixel- radius (when using 
a 40x objective) around a central intensity peak of 5 pixels. A distance of at least 10 
pixels was required between adjacent spot centers. Spot peaks had to exceed thresholds of 
relative intensity compared to the remaining body of the spot as well as to the entire 
image. The average, maximum and total RFP intensity of each spot were measured. The 
spots with sufficiently high absolute maxima to pass the selected threshold were 
classified as positive spots. To form candidate cilia, we selected the brightest 15% of the 
pixels in each positive spot and merged those pixels into objects so that the brightest parts 
of adjacent spots could form single, larger cilia-shaped objects. To qualify the candidate 
cilia as true Ivs-positive cilia, the width of the objects created from merging the brightest 
pixels in each spot had to be at least 2 pixels and the length to half-width ratio had to 
exceed 3.  (i.e. a 3-pixel long by 2-pixel wide cilium was the minimum accepted cilium 
size and the length had to be at least 1.5 fold of the width). The mean GFP intensity 
within these Ivs-positive cilia was used to estimate the ciliary level of Smo protein. We 
found it necessary to subtract the background of the mean GFP intensity in the 3-pixel 
wide area around each candidate cilium to avoid some false positives. Those Ivs-positive 
cilia that exceed the final mean GFP intensity threshold set for each experiment were 
deemed Smo-positive cilia.  16 
 
Hoechst staining was used to determine the total number of nuclei per well. 
The final output measurements of the number of Ivs-positive cilia in the well, the number 
of Smo-positive cilia in the well and the mean GFP intensity of the accepted cilia within 
the well were used to calculate if a compound qualified as an inhibitor and to estimate the 
quality of inhibition. Inhibitors of smoothened accumulation into the cilia were initially 
chosen as compounds that had numbers of Ivs-positive cilia per nucleus (or per field of 
view) similar to the DMSO controls, but fewer Smo-positive cilia compared to the 
DMSO controls. Compounds that generated many fewer Ivs-positive cilia were judged as 
either defective in cilium assembly/trafficking or generally toxic depending on the 
morphology of the cells. Measurements of the geometry of the cilia as well as the total 
fluorescent intensities of each cilium in the Smo- and Ivs- channels were used to 
determine if any of the compounds were having unusual effects on cilia size, intensity or 
frequency of observation or combinations of all three characteristics.  
The thresholds and parameters used in selecting, classifying, and quantitating 
spots, candidate cilia and nuclei, were applied uniformly for every well in each set of 
plates prepared as a single batch with the same set of cells and reagents. We used 
diagnostic images during threshold selection to outline which objects (spots, candidate 
cilia, candidate nuclei etc) passed or failed each selection. At least 2 fields of positive 
controls (Shh+SANT-1) and negative controls (Shh+DMSO) were examined for 
threshold setting. Visual observation and Z-prime calculations measuring the ability of 
the assay to distinguish positive from negative controls were used for quality control on 
each batch of plates and set of thresholds. All the images for comparison were scanned 
with identical microscopic settings and analyzed with the same input parameters. 17 
 
 
 
 
 
Hh and Wnt activity assays 
Hh activity assays were performed using ShhLightII cells, Smo/LightII cells, 
SmoM2/LightII cells, and suFU-/- mouse embryonic fibroblasts. In the suFU-/- cells, Hh 
activity was measured after co-transfection with Gli driven firefly luciferase and TK-
renilla luciferase reporters (38). Wnt activity was measured in293 cells co-transfected 
with Top-flash and TK-renilla luciferase reporters (39). Cells were cultured and treated in 
96 well assay plates (Corning) and incubated with Duo-Glo luciferase 
substrates(Promega) to measure firefly and renilla luciferase activity sequentially using a 
TopCount NX  Microplate Scintillation and Luminescence Counter (Perkin Elmer). The 
renilla luciferase signal was used to normalize the firefly reporter activity.  
Bodipy-Cyclopamine Competition Assays 
Cos7 cells were transfected with a plasmid co-expressing Smo and a nuclear localized 
form of tagRFPT (pCIT-Smo).  An empty parental construct(pCIT), and a construct that 
co-expressesSmoM2, were used as controls to assess specificity and background noise.  
Three days after transfection, cells were incubated with 5 nMBodipy-cyclopamine, with 
or without other compounds for 1 hour at 37
oC.  Cells were washed, fixed and stained 
with Hoechst. Images were collected by an Opera High Content Screen System. Bodipy 
fluorescence was quantified specifically for transfected cells (determined by red 
tagRFPT+ nucleus) using a program developed by the authors with Acapella 2.0 18 
 
software. All of the images were scanned with identical microscopic settings and 
analyzed with the same input parameters. 
 
CGNP proliferation Assays 
CGNP primary cells were isolated from P7 Ptch1+/- mice as previously reported(40) and 
immediately seeded in poly-D-lysine coated imaging plates(Greiner Bio-one). 
Compounds were applied 2 hours post seeding, for either 36 (Fig.5a-b) or 72 hours (Fig. 
5d-e). After completion of each experimental regimen, cells were fixed with 4% 
paraformaldehyde (Electron Microscopy Sciences), and stained with anti-pH3 antibody 
(Upstate; 1:100) followed by a secondary antibody (Invitrogen) and Hoechst (Invitrogen). 
Images were then collected using a confocal microscope. Cell proliferation, as marked by 
a pH3 signal, was quantified with an in-house program developed by the authors using 
Acapella 2.0 software. Identical microscopic settings were used in each analysis and 
identical input parameters were implemented for each experiment. 
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Table Legend: 
IC50’s of newly identified Smo antagonists in various cell based assays. Please note that 
IC50’s in this paper were obtained through non-linear regression based on the following 
equation: Y=Bottom + (Top-Bottom)/(1+10^((X-LogIC50))), where the top and bottom 
are the Y values of plateaus of no inhibition and saturated inhibition separately. 
 
Table 1 
Cell Line  Stimulus  Measurement  DY131  SMANT
3T3/Smo::GFP/Ivs::tagRFPT  Shh  Inhibition of Shh-
induced Smo::GFP 
ciliary accumulation 
0.8 1.1 
3T3/Shh-LightII  Shh  Inhibition of Shh-
induced expression of 
Gli-luciferase reporter 
2 2 
3T3/Smo::GFP/Ivs::tagRFPT  SAG  Inhibition of SAG-
induced Smo::GFP 
ciliary accumulation 
2 
(100nM 
SAG) 
>60(100
nM 
SAG) 
3T3/Shh-LightII  SAG  Inhibition of SAG-
induced expression of 
Gli-luciferase reporter 
2(100nM 
SAG) 
3(200n
M 
SAG); 
4(1 µM 23 
 
SAG) 
3T3/Smo::GFP 
Overexpression 
/Ivs::tagRFPT 
None  Inhibition of  ciliary 
accumulation of 
Smo::GFP upon 
overexpression 
0.08 3 
3T3/ Smo::GFP 
Overexpression/Shh-LightII 
None Inhibition  of 
expression of Gli-
luciferase reporter 
induced by Smo::GFP 
overexpression 
>30 3 
3T3/SmoM2::GFP 
Overexpression 
/Ivs::tagRFPT 
None  Inhibition of  ciliary 
localization of 
SmoM2::GFP 
>30 >60 
3T3/ SmoM2::GFP 
Overexpression/Shh-LightII 
None Inhibition  of 
expression of Gli-
luciferase reporter 
induced by 
SmoM2::GFP 
overexpression 
>30 1.2 
Cos7/Smo expression  None  Competition of 
BODIPY-
cyclopamine-Smo 
binding 
0.1 >30 24 
 
Ptch1+/- CGNP  Shh  Shh induced cell 
proliferation marked 
by pH3 
<0.625 <0.625 
 
 
 
 
 
 
 
 
 
Figure Legends: 
 
Fig.1A high content Smo antagonist screen - image analysis and assay validation.(a)A 
field of cells in a typical well. The cell number was calculated by counting Hoechst 
stained nuclei. The PCwere precisely segmented as Ivs::tagRFPT positive structures and 
hSmo::EGFP intensity was quantified in the PC. (b) Representative images of the dose-
dependent inhibition of Smo::EGFP ciliary accumulation by GDC0449. The 
concentrations of GDC0449 used to obtain these images were 0, 0.15nM, 1.3nM, 12nM, 
111nM, 1µM from left to right. Scale bar: 10µm. (c)Key measurements from high 
content image analyses. The cell number was determined by counting Hoechst stained 
nuclei. Ivs::tagRFPT positive structures were precisely segmented as the PC and 25 
 
Smo::EGFP intensity within the PC was quantified. The Ivs+ cilium count and Smo+ 
cilium count were determined based on arbitrary thresholds; the mean (±S.D)shown is 
based on four replicates. 
 
Fig.2Identification of compounds disrupting the PC. (a-b) HPI-4, an inhibitor of 
ciliogenesis, was identified in the assay.Please note that, throughout this paper, Ctrl% is 
an additional normalization over the mean of DMSO (with or without Shh) treatment as 
100%, unless stated otherwise, such as “Ctl=1”.(c-d)Vinblastine (VBN), which disrupts 
microtubules, and leads to disruption of the PC, was also identified through general 
effects on Ivs::tagRFPt; themean (±S.D) for the Smo localization assay and Gli-luciferase 
transcriptional reporter assays was calculated from four replicates (a and c). HPI-4 and 
VBN were used at 50µM and 370nM, respectively, to generate the representative images 
in (b) and (d). Scale bar: 10µm. 
 
Fig.3DY131 displays a conserved mechanism for Smo inhibition similar with previously 
identified antagonists. (a) Structure of DY131 and GSK4716. (b-c) Representative 
images (b) and quantification (c) of DY131 and GSK4716 inhibition of Hh induced Smo 
accumulation at the primary cilium. 500nM SANT-1 was used as a positive controlfor 
pronounced inhibition. DY131 and GSK4716 were used at 3.75µM and 7.5µM, 
respectively, for data in (b). Scale bar: 5µm. (d)Gli-luciferase measurements indicate 
dose-dependent inhibition of Hh pathway activity by both DY131 and GSK4716. Data 
show the means (±S.D.) from quadruplicate samples. Image analysis was based on over 
300 cells per sample. (e) Representative images showing Smo::EGFP and SmoM2::EGFP 26 
 
overexpressing cells treated with vehicle or 1.1µM DY131. Scale bar: 5µm. (f) Image 
analysis of quadruplicate samples, plotting mean (±S.D.) of over 300 cells analyzed in 
each sample. (g)Dose-response curves displaying DY131 inhibition ofwild-typeSmo, and 
SmoM2 activity. Data show mean (±S.D.) in quadruplicate samples. Representative 
images (h) and quantification (i) of Bodipy-Cyc competition experiments.Cyc, SANT-1, 
and DY131 were each used at 1.1 µM in (h). Scale bar: 10µm. Data show the mean 
(±S.D.) in quadruplicate samples (i), analyzing 50-100 transfected cells in each sample.  
 
Fig.4 SMANT displays an unprecedented mechanism for Smo inhibition. (a) Structure of 
SMANT and SMANT-2. (b-c) Representative images (b) and quantification (c) of 
SMANT and SMANT-2 inhibition of Hh induced Smo accumulation at the primary 
cilium. 1µM SANT-2 was used as a positive control. SMANT and SMANT-2 were used 
at 7.5µM for data in (b). Scale bar: 5µm. (d) Representative images showing Smo::EGFP 
and SmoM2::EGFP overexpressing cells treated with vehicle or SMANT. SMANT was 
applied to wild-typeSmo and SmoM2 expressing cells at 7.5µM and 30µM respectively. 
Scale bar: 5µm. (e) Image analysis of quadruplicate samples shown in (d), plotting mean 
(±S.D.) of over 300 cells analyzed in each sample. (f-g) Representative images (f) and 
quantifications of Smociliary localization (g) showing Smo::EGFP/Ivs::tagRFPT cells 
treated with 100nM SAG combined with vehicle, SANT-1, GDC0449, or SMANT. 
SANT-1, GDC0449 and SMANT were used at 1µM, 120nM, and 60µM. (h)Gli-
luciferase measurement of dose-dependent inhibition of Hh pathway activity by SMANT 
upon Shh stimulation, overexpression of Smo and SmoM2 respectively, or treatment with 
0.2 µM or 1µM of SAG. Data show the means (±S.D.) from triplicate samples. (i)Gli-27 
 
luciferase measurements in suFU-/- mouse embryonic fibroblasts treated with DY131 and 
SMANT respectively. GDC0449 and GANT61 were used as negative and positive 
controls respectively. (j-k)Representative images (j) and quantification (k) of Bodipy-
Cyc competition experiments for SMANT. SANT-1 served as a control for competition 
activity. SMANT was used at 30 µM in (h). Scale bar: 5µm. Data show the mean (±S.D.) 
from quadruplicate samples (i), analyzing 100-200 transfected cells in each sample.  
 
 
 
 
Fig.5DY131 and SMANT inhibit proliferation of cerebellar granule-cell neural 
progenitors (CGNP) without conferring hypersensitivity to Shh stimulation. (a-b) 
representative images (a) and quantification of phospho-histone H3(pH3) positive cells (b) 
upon co-treatment with 0.625µM DY131 or SMANT with Shh ligand. (b) P<=0.001 in t-
test for all samples treated with DY131 or SMANT at 0.625µM and above compared 
with DMSO treated controls. (c-e) In contrast to Cyc, GDC0449, DY131, and SMANT 
do not confer prolonged hypersensitivity to Shh stimulation in either Gli responsive 
reporter(c) or CGNP proliferation assays (d-e). Hh signaling activity and CGNP 
proliferation were measured after treatment with vehicle, Cyc (5µM), GDC0449 
(500nM), DY131 (10µM), or SMANT (10µM) separately. Samples were analyzed in 
quadruplicate; data show the mean (±S.D.). For the Gli-luciferase reporter assay (c), cells 
stimulated by Shh for a relatively short time period (12 hours) displayed a modest but 
significant inductive response (#p<0.003 in a t test comparing to a DMSO primed 0 nM 28 
 
Shh treatment). The response was enhanced by pre-treating cells with Cyc (##P<0.003 in 
t test comparing toDMSO priming and stimulation with the same concentration of Shh) 
whereas pretreatment with GDC0449, DY131, or SMANT showed no enhancing activity 
(P>0.05 in t test comparing samples primed with DMSO and stimulated with the same 
concentration of Shh). For the CGNP assay (d-e), cells were treated for 3 days. 
+p<0.0001 in a t test comparing the effects of DMSO (control) or any of the antagonists 
of Smo ciliary accumulation. 
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Supplementary Figure Legends: 
 
Supplementary Fig.1 Differential modulation of Smo cilial translocation and its signaling 
by several antagonists. (a) A schematic showing different Smo ciliary translocation 
behaviors induced by different Hh antagonists. Although all inhibited Smo activity, 
SANT-1, SANT-2, and GDC0449 inhibited Smo ciliary accumulation, whereas the direct 
Smo antagonist Cyc and FKL, a PKA activator,  that indirectly affects pathway activity, 
both promote Smo accumulation to the PC. (b-c) Treatment with Hh antagonists (Cyc: 5 
µM; FKL: 100 µM ; SANT-1: 500nM; GDC0449: 500nM) modifies Smo cilial 
localization (b) and inhibit Shh-stimulated pathway activity (P<1E-4 in t test) (c). SAG 
was included as a control agonist that has been shown to bind Smo and promote ligand 
independent Smo accumulation on the PC. Data show the mean from quadruplicate 
treatments (± the standard deviation, S.D.). 
 
 
Supplementary Fig.2. The workflow for a Smoothened cell-based screen monitoring 
accumulation at the primary cilium. Small molecule libraries were applied to 
Smo::EGFP/Ivs::tagRFPT cells. Potential antagonists of Smo cilial accumulation were 
identified in an assay based on movement of Smo::EGFP. 
 
Supplementary Fig.3. Validation of high content Smo antagonist screen with SANT-1. 
(a) Representative images of the dose-dependent inhibition of Smo::EGFP cilial 
accumulation by SANT-1. The concentrations of SANT-1 used to obtain these images 
were 0, 1.5nM, 14nM, 123nM, 1111nM from left to right. Scale bar: 5µm. (b) Key 3 
 
measurements from high content image analyses. The mean (±S.D) shown is based on 
four replicates. 
 
Supplementary Fig.4 Plots of relative Smo::EGFP+ cilium count normalized upon 
Shh+DMSO treated samples for putative Smo antagonist screen. Each dot represents the 
measurement of over one thousand cells in each well. Compound libraries were assayed 
at 10µM for this plot. SANT-1 and SAG were used at 1µM and Cyc was used at 10µM.  
 
Supplementary Fig.5 Indentification of AntagVIII. (a) structure. (b-d) AntagVIII 
inhibited both Smo cilial accumulation (b and c) and Hh pathway activity (d). Each 
treatment was analyzed in quadruplicate, measuring over 300 cells for each sample. 
AntagVIII was used at 1.875 µM for the representative image in (b). Scale bar: 5µm (e) 
high content analyses on AntagVIII’s dose dependent inhibition of Smo localization on 
the PC. 
 
Supplementary Fig.6  Identification of AY9944. (a) Structure. (b-d) AY9944 inhibited 
both Smo cilial accumulation (b and c) and the Hh pathway activity (d). Each treatment 
was analyzed in quadruplicate, measuring over 300 cells for each sample. AY9944 was 
used at 10 µM for the representative image in (b). Scale bar: 5µm (e) high content 
analyses on AY9944’s dose dependent inhibition of Smo localization on the PC. 
 
Supplementary Fig.7 Identification of Itraconazole (ICZ) and Ketoconazole (KCZ). (a) 
Structures. (b-d) ICZ and KCZ inhibited both Smo cilial accumulation (b and c) and Hh 4 
 
pathway activity (d). Each treatment was analyzed in quadruplicate, measuring over 300 
cells for each sample. ICZ and KCZ were used at 3.3µM and 10 µM for representative 
images (b). Scale bar: 10µm (e) high content analysis of the dose dependent inhibition of 
Smo accumulation in the PC on ICZ or KCZ treatment. 
 
Supplementary Fig.8 High content analyses indicate specific inhibition of Smo cilial 
localization by DY131 and GSK4716.  High content measurements are displayed for the 
cell count, Ivs::tagRFPT positive cilial count, cilial Ivs::tagRFPT intensity and 
Smo::EGFP intensity in the PC. Samples were analyzed in quadruplicate images 
comprising 50-100 transfected cells.  Data are plotted as the mean (±S.D.).  
 
Supplementary Fig.9 DY131 does not inhibit Wnt signaling activity. Wnt signaling 
activity was measured in a Top-flash reporter assay
1. A gradient of DY131 was applied to 
the cells with (Fold plotted) or without Wnt3a ligand (Control% plotted) conditioned 
medium. Means (±S.D.) from quadruplicate treatments are shown. 
 
Supplementary Fig.10 Several ERR/ER ligands including tamoxifen,  
4-hydroxytamoxifen(4-OHT) , diethylstilbestrol, and hexestrol do not alter Smo cilial 
localization in presence or absence of Hh ligand. (a) Structures of ERR/ER ligands. (b) 
Mean (±S.D.) of relative Smo::EGFP positive cilium count after treating cells with 
various doses of ERR/ER ligands in the absence (Fold plotted) or presence (Control% 
plotted) of Hh ligand. Each treatment was analyzed in quadruplicate, examining over 600 5 
 
cells per sample. (c) Representative images. All compounds were used at a concentration 
of 15μM. Scale bar: 5µm. 
 
Supplementary Fig.11 Accumulation of SmoM2 in the PC is refractory to SANT-1 or 
GDC0449 inhibition.  Representative images (a and c) and quantification (b and d) of the 
cilial intensity of Smo::EGFP and SmoM2::EGFP. SANT-1 and GDC0449 were used at 
1.1µM for the representative images; quadruplicate samples were analyzed and data show 
the means (±S.D.) of the EGFP intensity, examining over 300 cells in each treatment. 
Scale bar: 5µm.  
 
Supplementary Fig.12 SmoM2 mutation confers resistance to inhibition by Cyc, SANT-
1, or GDC0449. Hh pathway activity was induced by Hh ligand, over-expressing Smo or 
SmoM2. Dose dependent inhibition of Hh/Smo/SmoM2 signaling by Cyc, SANT-1, or 
GDC0449 was measured in quadruplicate samples. Data show the mean (±S.D.).  
 
Supplementary Fig13 DY131 inhibits SAG induced Smo cilial accumulation and 
signaling. Representative images (a) and image quantification (b) showing the mean 
(±S.D.) determined in quadruplicate samples, examining over 300 cells per sample. Scale 
bar: 5µm. Mean (±S.D.) of Gli luciferase activity measured in quadruplicated samples 
(c). 
 
Supplementary Fig.14 High content analyses indicate specific inhibition of Smo cilial 
localization by SMANT and SMANT-2.  High content measurements are displayed for 6 
 
the cell count, Ivs::tagRFPT positive cilium count, cilial Ivs::tagRFPT intensity and 
Smo::EGFP intensity in the PC. Samples were analyzed in quadruplicate images 
comprising 50-100 transfected cells.  Data are plotted as the mean (±S.D.).  
 
Supplementary Fig.15 SMANT does not activate nor profoundly inhibit Wnt signaling 
activity. Wnt signaling activity was measured in a Top-flash reporter assay
1. A gradient 
of SMANT was applied to the cells with (Fold plotted) or without Wnt3a ligand 
(Control% plotted) conditioned medium. Means (±S.D.) from quadruplicate treatments 
are shown.  
 
Supplementary Fig16 SMANT does not inhibit Cyc induced Smo cilial accumulation, 
whereas DY131, SANT-1, and GDC0449 effectively compete with Cyc. (a) 
representative images of cells treated with 5 µM  Cyc and DMSO, GDC0449 (7.5µM), 
SANT-1(7.5µM), DY131(7.5µM),  or SMANT (15µM) respectively. (b) image 
quantification showing the mean (±S.D.) determined in quadruplicate samples, examining 
over 300 cells per sample. Scale bar: 5µm.  
 
Supplementary Fig17 Examination of the effects of distinct Smo antagonists on Smo 
localization and Hh pathway activity. (a) Measurement of Hh signaling in Gli 
transcription reporter assays following treatment with either vehicle or Hh antagonists: 
Cyc (5µM), FKL (100µM), SANT-1 (500nM), and GDC0449 (500nM). Samples were 
analyzed in quadruplicate; mean is shown ±S.D. Pathway stimulation with Sonic 
hedgehog (Shh) was shorter (12 hrs) than in routine assays but a significant response was 7 
 
observed in this short time frame (#p<0.04 and ##p<1E-4 in t test). * indicates 
statistically significant hyperactivity in a t test comparing pre-treated with vehicle treated 
cells (*p<0.02; **p<0.006 in t test). SANT-1 and GDC0449 pre-treated cells showed 
either a significant but lower induction (+p<0.05 in t test), or no reduction in activity 
(P>0.1 in t-test for the rest). (b-e) Representative images of Smo::EGFP in the PC (b and 
c) and quantified Smo::EGFP ciliary intensity  (d and e);  a slow turnover of Smo::EGFP 
was observed following Cyc (5µM) and FKL (100 µM) withdrawal. No measurable 
change was observed in Ivs::tagRFPT, an independent primary cilium marker, over the 
same time period. All the Ivs::tagRFPT images in this report were shifted leftwards by 5 
pixels to clearly show both Smo::EGFP and Ivs::tagRFPT signals. Experiments were 
conducted in quadruplicate, analyzing over 300 cells in each sample.  Fluorescent 
intensity was plotted as the mean (±S.D.). Scale bar: 5µm.  
 
 
Supplementary Fig18 Cellular sensitivity to SAG stimulation after priming with various 
Hh antagonists. Hh signaling activity was measured in a Gli transcription reporter assay 
after pre-treatment with vehicle or various Hh antagonists including Cyc (5µM), FKL 
(100µM), SANT-1 (500nM), and GDC0449 (500nM). Samples were assayed in 
quadruplicate and means (±S.D.) were displayed. A short 12 hr stimulation with SAG 
induced a weak but significant response (#p<0.0002 in t test). * indicates statistical 
significant difference in t test when compared with cells treated with vehicle (*p<0.03; 
**p<0.005 in t test). In contrast, SANT-1 and GDC0449 treated cells showed a 8 
 
significantly lower induction (+p<0.05 in t test) or no statistical difference (p>0.05 in t-
test for remaining samples) when compared with cells treated with vehicle. 
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